Verona Pharma (VRNA) Rebounded from Challenging Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Verona Pharma Plc (VRNA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 5,507,591 | $520,907,957 | -17% | 19.31% |
| 2. | Darwin Global Management Abhishek Trehan | 4,129,618 | $387,440,761 | +6% | 16.26% |
| 3. | Farallon Capital Thomas Steyer | 1,810,000 | $171,189,800 | +67% | 0.74% |
| 4. | Hood River Capital Management David Swank | 1,562,467 | $147,778,129 | +2% | 2.06% |
| 5. | Caligan Partners David Johnson | 1,436,878 | $135,899,921 | 26.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 20,000 | $88,800.00 | 940,003 | 2024-11-18 | Filing | |
| $4.80 | 39,360 | $188,880.77 | 920,003 | 2024-11-06 | Filing | |
| $4.74 | 41,880 | $198,385.56 | 41,880 | 2024-11-06 | Filing | |
| $2.87 | 36,000 | $103,320.00 | 880,643 | 2024-08-12 | Filing | |
| $1.84 | 33,736 | $61,973.03 | 144,800 | 2023-11-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.14 | 10,808 | $142,057.11 | 79,776 | 2025-08-01 | Filing | |
| $13.14 | 9,464 | $124,391.98 | 84,856 | 2025-08-01 | Filing | |
| $13.14 | 9,584 | $125,969.22 | 417,903 | 2025-08-01 | Filing | |
| $13.14 | 208,912 | $2,745,876.65 | 12,464,968 | 2025-08-01 | Filing | |
| $13.14 | 58,336 | $766,750.88 | 2,607,472 | 2025-08-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,134,405 | $580,121,254 | 0.28% | |
| 2. | 3,383,950 | $320,053,991 | 12.8% | |
| 3. | 3,051,878 | $288,646,621 | 4.11% | |
| 4. | 2,715,324 | $256,802,739 | 4.5% | |
| 5. | 2,617,297 | $247,543,950 | 0.03% |
News See All
Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter.
13 Best Mid Cap Growth Stocks to Buy According to Hedge Funds
On August 26, Courtney Garcia, Payne Capital Management senior wealth advisor, joined CNBC television for an interview to discuss whether investors should continue buying in the current market scenario...
Merck’s $10B Verona Deal: A High-Stakes Play in Respiratory Care
Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co.
14 Best Multibagger Stocks to Buy According to Hedge Funds
The market in 2025 is primed for multibagger opportunities—and it’s not just tech carrying the load.
Verona Pharma (VRNA) Jumps 125% YTD; Merck $10-Billion Acquisition Bolsters Sentiment
Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading day of 2024, with its recent rally largely bolstered by Merck & Co.
Verona Pharma plc (VRNA) Is Unlikely To Face Antitrust Action For Merck Deal, Says Jim Cramer
Verona Pharma plc (NASDAQ:VRNA)’s shares experienced a boost in July when pharmaceutical giant Merck announced that it would acquire the firm for a $10 billion price tag.
Verona Pharma plc (VRNA): A Bull Case Theory
We came across a bullish thesis on Verona Pharma plc (VRNA) on Capital Employed’s Substack by Patients Capital Management. In this article, we will summarize the bulls’ thesis on VRNA.
Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed President Trump's tariffs and their impact on the economy and America's global politics.
Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition
Verona Pharma plc (NASDAQ:VRNA) is a small biotechnology company that focuses on respiratory diseases.
Hedge Fund Resource Center Billionaire Hedge Funds
